Abstract
Distinguishing between allograft rejection, kidney disease progression, and preeclampsia in a non-invasive manner can be difficult in pregnant kidney transplant recipients. Donor-derived cell-free DNA (dd-cfDNA) is a biomarker that can be measured non-invasively to assess risk of allograft rejection. However, using dd-cfDNA to monitor allograft status in pregnant kidney transplant recipients requires distinguishing between fetal, donor, and recipient cfDNA fragments. In this study, we aimed to measure dd-cfDNA in a cohort of pregnant kidney transplant recipients using a combination of NIPT and transplant monitoring technology utilizing cfDNA.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
